# Nuclide record paper-therap-lancet-2021 (paper). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/key-papers/paper-therap-lancet-2021/>
  a schema:ScholarlyArticle ;
  nuclide:kind "paper" ;
  schema:identifier "paper-therap-lancet-2021" ;
  schema:name "TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer"@en ;
  schema:description "In men whose prostate cancer had grown after chemotherapy, a radioactive drug that homes in on prostate cancer cells (lutetium-177 PSMA-617) shrank the PSA marker in more men, and caused fewer serious side effects, than the standard chemotherapy drug it was compared with."@en ;
  schema:url <https://nuclide.cc/key-papers/paper-therap-lancet-2021/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/33581798/>, <https://pubmed.ncbi.nlm.nih.gov/38043558/> ;
  nuclide:tag "prostate cancer", "radioligand therapy", "randomised trial" ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(21)00237-3> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, et al." ;
  nuclide:related <https://nuclide.cc/trials/therap/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/technologies/lu177-radioligand-therapy/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/drugs/cabazitaxel/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/people/michael-morris/>, <https://nuclide.cc/people/hofman-michael/>, <https://nuclide.cc/people/louise-emmett/>, <https://nuclide.cc/people/sandhu-shahneen/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> .